This study looks at anti-HER2 therapy plus endocrine therapy with or without palbociclib in patients with hormone receptor-positive HER2+ metastatic breast cancer. This study aims to extend the time before the disease progresses. More details
THYmine2 is an observational study to assess whether the thymine loading test can prospectively categorize patients who cannot tolerate 5-FU treatment (e.g. FOLFOX, CapeOx, FLOX). This treatment is commonly used in breast cancer treatment. Reactions occur in approximately 10% of patients and can result in life-threatening events. More details
The purpose of this study is to assess the efficacy and safety of pembrolizumab (Keytruda) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. More details
A phase 3 study looking at the effectiveness of treatment with etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer who have stable brain metastases and have previously been treated with an Anthracycline, a Taxane, and Capecitabine. More details
This is a proof-of-concept pilot study to determine if short-term treatment with denosumab (trade names Prolia and Xgeva) is a feasible chemoprevention option against breast cancer for BRCA1 and BRCA2 mutation carriers, as well as high risk, non-BRCA carriers. More details
A phase II study evaluating the efficacy and safety of Ipilimumab and Nivolumab with neoadjuvant weekly paclitaxel after anthracycline-based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one-year total duration of Nivolumab. More details
You can join this phase 3 study if you've been diagnosed with early invasive breast cancer and you have had or will have, surgery for this, and you also plan to have chemotherapy as part of your anti-cancer treatment. More details
This is a study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with locally advanced or metastatic solid tumors. More details
Lifepool is a research resource for study into breast cancer and women's health. It aims to recruit 100,000 Australian women. This will establish one of the largest cohorts in the world, providing research tools to answer critical questions about breast cancer. Lifepool aims to gather information on health and lifestyle, mammogram data and asks permission to track the health of each participant through linkage with other health databases. More details
An open-label, randomized, window of opportunity study between diagnosis and definite surgery, to assess the effect of antiestrogen therapies, alone and in combination with microionized progesterone (prometrium) in patients with newly diagnosed ER+PR+ breast cancer. More details
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion. More details
The study is evaluating the impact of risk-reducing bilateral salpingo-oophorectomy (RRBSO) on sexual function, menopause symptoms and quality of life issues, bone health, cardiovascular health, sleep quality, depression/anxiety symptoms and cognitive function in high-risk, pre-menopausal women. More details
The purpose of this study is to determine if breast cancer genetic material (known as circulating tumour DNA (ctDNA)) can be detected in the bloodstream. It is hoped that this research will demonstrate the utility of this circulating material as an early marker of breast cancer activity. More details
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to email@example.com
Interested in a clinical trial?
Subscribe for updates & stay in the loop with new studies.